408

(RTTNews) – Verrica Pharmaceuticals Inc. (VRCA) Friday said the Food and Drug Administration has extended the review period for the New Drug Application (NDA) for VP-102 for the treatment of molluscum contagiosum. The decision date has been extended by the FDA by three months to September 23, 2021. On May 26, the FDA intimated Verrica that the…